open access

Vol 6, No 4 (2017)
Review articles (submitted)
Published online: 2017-11-17
Get Citation

The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus

Agnieszka Stelmaszyk, Marzena Dworacka
DOI: 10.5603/DK.2017.0024
·
Clinical Diabetology 2017;6(4):142-146.

open access

Vol 6, No 4 (2017)
Review articles (submitted)
Published online: 2017-11-17

Abstract

The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.

Abstract

The following paper is an attempt to revise current data and the results of clinical trials concerning the impact of dapagliflozin on long-term cardiovascular complications of type 2 diabetes mellitus. Short-term clinical trials, including relatively small groups of patients, suggest positive influence of dapagliflozin on the cardiovascular system. Currently ongoing long-term trials are likely to confirm these data, but so far we can assume that dapagliflozin not only acts as an efficient antihyperglycaemic drug, but also protects the circulatory system in patients with type 2 diabetes mellitus.

Get Citation

Keywords

dapagliflozin, risk factors, cardiovascular events, atherosclerosis

About this article
Title

The impact of dapagliflozin on cardiovascular system in the course of type 2 diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 6, No 4 (2017)

Pages

142-146

Published online

2017-11-17

DOI

10.5603/DK.2017.0024

Bibliographic record

Clinical Diabetology 2017;6(4):142-146.

Keywords

dapagliflozin
risk factors
cardiovascular events
atherosclerosis

Authors

Agnieszka Stelmaszyk
Marzena Dworacka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl